• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Robbins Larry

    5/19/25 5:48:21 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ROBBINS LARRY

    (Last) (First) (Middle)
    ONE CVS DRIVE

    (Street)
    WOONSOCKET RI 02895

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CVS HEALTH Corp [ CVS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Deferred Stock Units $0 05/15/2025 A(1) 2,769.9686 (2) (2) Common Stock 2,769.9686 $60.47 5,766.7068 D
    Explanation of Responses:
    1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.
    2. Consists of deferred stock units, each to be converted into one share of common stock and issued upon the Reporting Person's retirement from the Issuer's Board of Directors, as elected by the Reporting Person.
    /s/ Larry M. Robbins 05/19/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    8/18/2025$79.00Neutral → Buy
    UBS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    11/18/2024$60.00 → $66.00Equal Weight → Overweight
    Wells Fargo
    10/10/2024$63.00 → $82.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded CVS Health from Neutral to Outperform and set a new price target of $82.00

    8/14/25 8:02:24 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously

    2/13/25 7:04:02 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    SEC Filings

    View All

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    8/15/25 4:10:49 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 424B3 filed by CVS Health Corporation

    424B3 - CVS HEALTH Corp (0000064803) (Filer)

    8/11/25 8:14:25 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 13F-HR filed by CVS Health Corporation

    13F-HR - CVS HEALTH Corp (0000064803) (Filer)

    8/1/25 4:16:55 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Mahoney Michael F bought $2,001,000 worth of shares (30,000 units at $66.70), increasing direct ownership by 321% to 39,356 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    2/19/25 12:35:35 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ludwig Edward J bought $53,879 worth of shares (1,000 units at $53.88), increasing direct ownership by 5% to 21,630 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    5/2/24 4:31:44 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Financial Officer Newman Brian was granted 21,861 shares (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/3/25 4:35:13 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Medical Officer Compton-Phillips Amy was granted 53,091 shares (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/3/25 4:33:21 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior yearSecond quarter GAAP diluted EPS of $0.80 and Adjusted EPS of $1.81Generated year-to-date cash flow from operations of $6.5 billionOperational Highlights Aetna® delivers distinctive advances in care navigationCVS Pharmacy® agreed to acquire certain prescription files and store locations from Rite AidCVS Caremark® demonstrates market-leading innovation in strong renewal and sales season2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20Raised cash flow from operation

    7/31/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna Launches New AI and Digital Tools to Improve Access and Care

    Aetna Care Paths, a first-to-market care option available in the Aetna Health app, makes it easier and simpler for members to get the care they needAI enabled clinical solutions enhance the human touch, giving nurses 90 more minutes a day to spend with membersWOONSOCKET, R.I., July 29, 2025 /PRNewswire/ -- To make the health care system easier to navigate, Aetna, a CVS Health® company (NYSE:CVS), today announced the introduction of Aetna Care Paths and AI-driven programs as part of the company's ongoing technology investment to improve the experience for medical professionals and their patients.

    7/29/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EngageWell, Rocket Doctor, and CVS Health Foundation Launch Virtual Healthy Aging Program for Adults over 60

    Health checks include assessments for heart health, memory, cognitive function, and mental healthNo travel required — all appointments are virtual and confidentialCommunity Health Workers provide personalized follow-up support and connect patients to local resourcesThe program is now available in New York City, with plans to expand throughout 2025Free for patients on Medicaid, covered by insurance for patients on Medicare New York, NY, July 10, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE:TRUE, OTC:TREIF, Frankfurt: 939)) ("Treatment") is pleased to announce that building off their successful graduation from AARPs AgeTech Accelerator, its subsidiary, Rocket Doctor Inc., has partner

    7/10/25 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

    Foundation announces $2 million in new Health Zones funding to support at-risk populations WOONSOCKET, R.I., March 6, 2025 /PRNewswire/ -- The CVS Health® Foundation today announced $2 million in new Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its agency partners, all located in Hartford, Connecticut. This funding will help address critical gaps in the health care and social system for individuals with chronic health conditions by increasing access to comprehensive health care services and resources. "A variety of interconnected fac

    3/6/25 8:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health announces Pharmacy and Consumer Wellness leadership appointments

    WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new

    12/3/24 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/9/23 11:16:32 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    View All

    CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

    Financial Highlights Second quarter total revenues increased to $98.9 billion, up 8.4% compared to prior yearSecond quarter GAAP diluted EPS of $0.80 and Adjusted EPS of $1.81Generated year-to-date cash flow from operations of $6.5 billionOperational Highlights Aetna® delivers distinctive advances in care navigationCVS Pharmacy® agreed to acquire certain prescription files and store locations from Rite AidCVS Caremark® demonstrates market-leading innovation in strong renewal and sales season2025 Full-Year Guidance Revised GAAP diluted EPS guidance range to $3.84 to $3.94 from $4.23 to $4.43Raised Adjusted EPS guidance range to $6.30 to $6.40 from $6.00 to $6.20Raised cash flow from operation

    7/31/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health declares quarterly dividend

    WOONSOCKET, R.I., July 7, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on August 1, 2025, to holders of record on July 22, 2025. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, the Company had more than 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care me

    7/7/25 9:39:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health to hold second quarter 2025 earnings conference call

    WOONSOCKET, R.I., June 30, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Thursday, July 31st, 2025, at 8:00 a.m. ET to discuss second quarter 2025 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS HealthCVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of March 31, 2025, th

    6/30/25 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples